声遗传学是一种新型抗心律失常治疗方法
Sonogenetics is a novel antiarrhythmic treatment
AI总结：
本文提出一种声遗传学抗心律失常方法，利用可穿戴超声相控阵无创聚焦激活心肌Piezo1通道以恢复心律，并通过机电模型验证其安全无痛且低于FDA限值。
摘要：
心律失常是一种危险且可能致命的疾病。目前广泛使用的治疗方法是植入式心脏复律除颤器（ICD），但它具有侵入性，并会影响患者的生活质量。本文提出的声遗传学治疗技术将经胸超声聚焦于心脏，无创刺激局灶区域心肌细胞质膜上的内源性机械敏感性Piezo1离子通道，从而恢复正常心律。与将植入式ICD导线固定在心肌内某一位置不同，超声焦点区域的大小和位置可通过调节可穿戴超声相控阵上每个压电芯片的信号相位来动态选择，从而实现新颖且高效的除颤。基于所建立的声遗传学治疗跨学科机电模型，我们的分析表明，所提出的超声强度和频率对人类安全、无痛，且远低于美国食品药品监督管理局规定的限值。
英文摘要：
Arrhythmia of the heart is a dangerous and potentially fatal condition. The current widely used treatment is the implantable cardioverter defibrillator (ICD), but it is invasive and affects the patient's quality of life. The sonogenetic treatment technique proposed here focuses transthoracic ultrasound on the heart, noninvasively stimulates endogenous stretch-activated Piezo1 ion channels on the focal region's cardiomyocyte plasma membrane, and restores normal heart rhythm. In contrast to anchoring the implanted ICD lead at a fixed position in the myocardium, the size and position of the ultrasound focal region can be selected dynamically by adjusting the signal phases of every piezoelectric chip on the wearable ultrasonic phased array, and it allows novel and efficient defibrillations. Based on the developed interdisciplinary electromechanical model of sonogenetic treatment, our analysis shows that the proposed ultrasound intensity and frequency will be safe and painless for humans and well below the limits established by the U.S. Food and Drug Administration.
机构、总结、中文摘要均由AI分析而来，可能存在错误，请以论文正文为准。
